Sfmg LLC Sells 381 Shares of Johnson & Johnson $JNJ

Sfmg LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,514 shares of the company’s stock after selling 381 shares during the quarter. Sfmg LLC’s holdings in Johnson & Johnson were worth $1,912,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in JNJ. W.H. Cornerstone Investments Inc. lifted its position in Johnson & Johnson by 0.7% during the second quarter. W.H. Cornerstone Investments Inc. now owns 7,896 shares of the company’s stock worth $1,206,000 after purchasing an additional 58 shares during the period. YANKCOM Partnership increased its holdings in shares of Johnson & Johnson by 0.8% during the second quarter. YANKCOM Partnership now owns 7,042 shares of the company’s stock worth $1,076,000 after buying an additional 58 shares in the last quarter. Greenup Street Wealth Management LLC raised its position in Johnson & Johnson by 3.1% in the second quarter. Greenup Street Wealth Management LLC now owns 2,021 shares of the company’s stock valued at $309,000 after purchasing an additional 60 shares during the last quarter. Ellis Investment Partners LLC boosted its position in Johnson & Johnson by 0.7% during the 2nd quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after buying an additional 62 shares during the period. Finally, Cypress Wealth Services LLC grew its stake in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock worth $1,013,000 after purchasing an additional 62 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Up 0.4%

Shares of NYSE JNJ opened at $203.88 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company has a market cap of $491.21 billion, a P/E ratio of 19.68, a P/E/G ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $206.94. The business has a 50-day simple moving average of $188.25 and a two-hundred day simple moving average of $171.55.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on JNJ shares. Raymond James Financial upped their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Daiwa Capital Markets upgraded Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price on the stock in a research note on Monday, October 20th. Finally, Bank of America lifted their price objective on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Four analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.